Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

First Posted Date
2011-02-09
Last Posted Date
2018-08-24
Lead Sponsor
Vanderbilt University
Target Recruit Count
12
Registration Number
NCT01292694
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer

First Posted Date
2011-01-24
Last Posted Date
2014-06-18
Lead Sponsor
European Institute of Oncology
Target Recruit Count
320
Registration Number
NCT01281787
Locations
🇮🇹

European Institute of Oncology, Milan, Italy

Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas

Early Phase 1
Terminated
Conditions
Interventions
First Posted Date
2011-01-13
Last Posted Date
2019-05-02
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
18
Registration Number
NCT01276613
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

First Posted Date
2010-11-04
Last Posted Date
2018-08-28
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
6
Registration Number
NCT01234922
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Telmisartan Versus Losartan in Kidney Transplantation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-10-20
Last Posted Date
2014-02-25
Lead Sponsor
Mario Negri Institute for Pharmacological Research
Target Recruit Count
20
Registration Number
NCT01224860
Locations
🇮🇹

Mario negri Institute - Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions

Not Applicable
Completed
Conditions
First Posted Date
2010-10-07
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
40
Registration Number
NCT01216878
Locations
🇺🇸

BioKinetic Clinical Applications, Inc., Springfield, Missouri, United States

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions

Not Applicable
Completed
Conditions
First Posted Date
2010-10-07
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
40
Registration Number
NCT01216852
Locations
🇺🇸

Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States

Local Vasoconstriction in Postural Tachycardia Syndrome

First Posted Date
2010-09-28
Last Posted Date
2021-06-10
Lead Sponsor
New York Medical College
Target Recruit Count
74
Registration Number
NCT01210430
Locations
🇺🇸

New York Medical College/Bradhurst building, Hawthorne, New York, United States

Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma

First Posted Date
2010-09-13
Last Posted Date
2024-03-26
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
30
Registration Number
NCT01199978
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Intensive Vasodilator Therapy in Patients With Essential Hypertension

First Posted Date
2010-08-12
Last Posted Date
2012-04-19
Lead Sponsor
Aarhus University Hospital
Target Recruit Count
48
Registration Number
NCT01180413
Locations
🇩🇰

Aarhus University Hospital - dept. cardiology (A), Aarhus, Denmark

© Copyright 2024. All Rights Reserved by MedPath